6B8Y

TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH N-(3-fluoropyridin-4-yl)-2-[6-(trifluoromethyl)pyridin-2-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.65 Å
  • R-Value Free: 0.208 
  • R-Value Work: 0.179 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Heterobicyclic inhibitors of transforming growth factor beta receptor I (TGF beta RI).

Harikrishnan, L.S.Warrier, J.Tebben, A.J.Tonukunuru, G.Madduri, S.R.Baligar, V.Mannoori, R.Seshadri, B.Rahaman, H.Arunachalam, P.N.Dikundwar, A.G.Fink, B.E.Fargnoli, J.Fereshteh, M.Fan, Y.Lippy, J.Ho, C.P.Wautlet, B.Sheriff, S.Ruzanov, M.Borzilleri, R.M.

(2018) Bioorg. Med. Chem. 26: 1026-1034

  • DOI: 10.1016/j.bmc.2018.01.014

  • PubMed Abstract: 
  • The TGFβ-TGFβR signaling pathway has been reported to play a protective role in the later stages of tumorigenesis via increasing immunosuppressive Treg cells and facilitating the epithelial to mesenchymal transition (EMT). Therefore, inhibition of TG ...

    The TGFβ-TGFβR signaling pathway has been reported to play a protective role in the later stages of tumorigenesis via increasing immunosuppressive Treg cells and facilitating the epithelial to mesenchymal transition (EMT). Therefore, inhibition of TGFβR has the potential to enhance antitumor immunity. Herein we disclose the identification and optimization of novel heterobicyclic inhibitors of TGFβRI that demonstrate potent inhibition of SMAD phosphorylation. Application of structure-based drug design to the novel pyrrolotriazine chemotype resulted in improved binding affinity (Ki apparent = 0.14 nM), long residence time (T 1/2  > 120 min) and significantly improved potency in the PSMAD cellular assay (IC 50  = 24 nM). Several analogs inhibited phosphorylation of SMAD both in vitro and in vivo. Additionally, inhibition of TGFβ-stimulated phospho-SMAD was observed in primary human T cells.


    Organizational Affiliation

    Molecular Structure & Design, Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA.,Department of Chemistry, Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA.,Lead Discovery & Optimization, Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA.,Department of Chemistry, Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA. Electronic address: lalgudi.harikrishnan@bms.com.,Immuno-Oncology Small Molecule Biology, Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ, USA.,BBRC, Special Economic Zone, Biocon Park, Jigani Link Road, Bangalore, India.




Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
TGF-beta receptor type-1
A
307Homo sapiensMutation(s): 1 
Gene Names: TGFBR1 (ALK5, SKR4)
EC: 2.7.11.30
Find proteins for P36897 (Homo sapiens)
Go to Gene View: TGFBR1
Go to UniProtKB:  P36897
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
D0A
Query on D0A

Download SDF File 
Download CCD File 
A
N-(3-fluoropyridin-4-yl)-2-[6-(trifluoromethyl)pyridin-2-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
C17 H10 F4 N6
KNTWBIUWHSYQJE-UHFFFAOYSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 1.65 Å
  • R-Value Free: 0.208 
  • R-Value Work: 0.179 
  • Space Group: P 21 21 21
Unit Cell:
Length (Å)Angle (°)
a = 42.110α = 90.00
b = 77.030β = 90.00
c = 90.440γ = 90.00
Software Package:
Software NamePurpose
Aimlessdata scaling
XDSdata reduction
BUSTERrefinement
AMoREphasing
PDB_EXTRACTdata extraction

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2017-10-09 
  • Released Date: 2018-02-07 
  • Deposition Author(s): Sheriff, S.

Revision History 

  • Version 1.0: 2018-02-07
    Type: Initial release
  • Version 1.1: 2018-02-21
    Type: Database references